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Abstract v9-Tetrahydrocannabinol (THC), the major active
component of marijuana, induced apoptosis in C6.9 glioma cells,
as determined by DNA fragmentation and loss of plasma
membrane asymmetry. THC stimulated sphingomyelin hydro-
lysis in C6.9 glioma cells. THC and N-acetylsphingosine, a cell-
permeable ceramide analog, induced apoptosis in several
transformed neural cells but not in primary astrocytes or
neurons. Although glioma C6.9 cells expressed the CB1
cannabinoid receptor, neither THC-induced apoptosis nor
THC-induced sphingomyelin breakdown were prevented by
SR141716, a specific antagonist of that receptor. Results thus
show that THC-induced apoptosis in glioma C6.9 cells may rely
on a CB1 receptor-independent stimulation of sphingomyelin
breakdown.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Cannabinoids, the active components of marijuana, exert a
wide spectrum of e¡ects such as alterations in cognition and
memory, analgesia, anticonvulsion, antiin£ammation, and al-
leviation of both intraocular pressure and emesis [1]. It is
currently established that cannabinoids exert their e¡ects by
binding to speci¢c plasma-membrane receptors [1]. To date,
two di¡erent cannabinoid receptors have been characterized
and cloned from mammalian tissues, viz. CB1 [2] and CB2 [3].
The recent discovery of a family of endogenous ligands of
cannabinoid receptors [4^6] as well as the potential therapeu-
tic applications of a number of cannabinoid ligands [7,8] have
focused a lot of attention on cannabinoids during the last few
years.
Glial cells play a major role in brain function since they are
involved in processes such as the homeostasis of the neuronal
microenvironment, the formation of the blood-brain barrier,
the guidance of neuron migration in the developing embryo,
and the secretion of neurotrophic factors for neuron healing
or development [9]. A potential direct and speci¢c action of
cannabinoids on glial cells is supported by some recent obser-
vations. Thus, the CB1 receptor mRNA is expressed in astro-
cytes and astrocytoma cells [10]. Astrocytes in culture have
also been shown to bind and take up anandamide, a putative
endogenous ligand of the CB1 receptor [11]. In astrocytoma
cells, cannabinoids lead to the stimulation of the mitogen-
activated protein kinase and to the induction of the immedi-
ate-early gene krox-24 [12]. In the course of our studies on the
metabolic e¡ects of cannabinoids on C6 glioma cells [13] we
have observed that cannabinoids inhibit the growth of these
cells. Hence, the present work was undertaken to further char-
acterize the anti-proliferative e¡ect of cannabinoids on C6
glioma cells.
2. Materials and methods
2.1. Materials
THC and 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide
thiazol blue (MTT) were from Sigma (St. Louis, USA). The mouse
neuroblastoma N18 TG2 cell line and the human astrocytoma U373
MG cell line were kindly given by Dr. V. Di Marzo (CNR, Naples,
Italy) and Dr. P. Casellas (Sano¢ Recherche, Montpellier, France),
respectively. The anti-CB1 cannabinoid receptor antibody was kindly
given by Dr. Allyn Howlett (St. Louis University, USA). SR141716
was kindly given by Sano¢ Recherche (Montpellier, France).
[Me-3H]Choline and the ECL detection kit were from Amersham
(Bucks, UK).
2.2. Cell cultures
The C6.9 cell subclone (10^20 passages) was cultured in F12 me-
dium supplemented with 10% fetal calf serum. Twenty four hours
before the experiment, cells were transferred to serum-free medium
consisting of F12 medium supplemented with insulin (5 Wg/ml), trans-
ferrin (5 Wg/ml), sodium selenite (5 ng/ml), and defatted and dialyzed
bovine serum albumin (1.0 mg/ml) [14]. The astrocytoma U373 MG
[12], the neuroblastoma N18 TG2 [15], newborn-rat cortical astrocytes
[16] and newborn-rat cortical neurons [17] were cultured as previously
described.
2.3. MTT assay
Cells were incubated with 5 Wg/ml MTT for 4 h at 37‡C. The
medium was then aspirated, the formazan crystals were solubilized
with 60 mM HCl in isopropanol and the absorbance at 570 nm was
monitored [14].
2.4. DNA isolation and analysis
Cells (£oating plus attached) were pooled, pelleted, lysed and in-
cubated at 50‡C for 1 h in a medium containing 50 mM Tris-HCl, pH
8.0, 50 mM EDTA, 0.5% (w/v) sodium lauryl sarcocylate, and 0.5 mg/
ml proteinase K. After treatment for 1 h with DNase-free RNase A at
50‡C, samples were mixed with 1% low-gelling temperature agarose at
62‡C and subjected to electrophoresis in 1.5% agarose gels.
2.5. Binding of £uorescent annexin V
Cells grown in slide £asks coated with poly-D-lysine were washed
twice with PBS and then with binding bu¡er (10 mM HEPES/NaOH,
pH 7.4, 140 mM NaCl and 2.5 mM CaCl2) prior to incubation with
£uorescein isothiocyanate-conjugated annexin V for 20 min at 4‡C.
After cell ¢xation with paraformaldehyde, permeabilization with etha-
nol/acetic acid and digestion with RNase A, propyl iodine was added
and samples were subject to £uorescence microscopy [18].
FEBS 20847 25-9-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 0 8 5 - 0
*Corresponding author. Fax: (34) (1) 3944672.
E-mail: mgp@solea.quim.ucm.es
Abbreviations: MTT, 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium
bromide thiazol blue; THC, v9-tetrahydrocannabinol
FEBS 20847FEBS Letters 436 (1998) 6^10
2.6. Determination of sphingomyelin hydrolysis
Cells were cultured in serum-containing medium and then trans-
ferred to serum-free medium for 24 h as described above. Then the
medium was changed and cells were incubated for a further 48-h
period in chemically-de¢ned medium supplemented with 1 WCi of
[3H-Me]choline per well. Reactions were started by the addition of
the agonists and sphingomyelin was subsequently extracted with
chloroform/methanol/water as described before [19].
2.7. Western blot analysis of the CB1 cannabinoid receptor
Cells were scraped and sonicated (2U5 s) on ice, and the particulate
fraction was obtained after centrifugation at 40 000Ug for 60 min
[16]. Western blot analysis of the CB1 receptor was performed as
described by Song and Howlett [20]. Blots were ¢nally subjected to
luminography with an ECL detection kit.
2.8. Statistical analysis
Results shown represent the means þ S.D. of the number of experi-
ments indicated in every case. Every experimental condition was rou-
tinely assayed in quadruplicate. Statistical analysis was performed by
ANOVA. A post hoc analysis was made by the Student-Neuman-
Keuls test.
3. Results and discussion
3.1. THC induces apoptosis in C6.9 glioma cells
Gliomas often show a gross variability characterized by the
presence of morphologically distinct cell types within the same
tumor [21]. Moreover, glioma cell lines such as C6 have been
reported to be heterogenous [14,22]. Hence we used in the
present study a subclone of C6 cells (the C6.9 subclone)
that has been previously characterized in terms of pro-
grammed cell death [14]. As shown in Fig. 1A, addition of
THC to the culture medium led to a dramatic drop of mito-
chondrial oxidative metabolism in C6.9 cells as determined by
the MTT test. This e¡ect of THC occurred 4^5 days after the
beginning of cell challenge to the cannabinoid (Fig. 1A), was
dose-dependent (Fig. 1B) and was accompanied by the death
of the cells, which rounded up, detached from their solid
support and took up trypan blue (Fig. 2 and data not shown).
Interestingly, the THC-induced decrease in optical density at
570 nm in the MTT test showed a non-linear, cooperative-like
pattern (Fig. 1A) that may be indicative of an apoptotic proc-
ess. Experiments were subsequently performed to characterize
the THC-induced cell death.
(i) THC-induced glioma cell death was linked to a loss of
plasma membrane asymmetry, as determined by the £uores-
cent annexin V binding assay (Fig. 2).
(ii) THC induced ladder-patterned DNA fragmentation in
C6.9 glioma cells (Fig. 3), a process that is typical of cell death
by apoptosis.
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Fig. 1. THC-induced depression of mitochondrial oxidative metabolism in C6.9 glioma cells. A: Cells were cultured in serum-free medium in
the absence (a) or in the presence (b) of 1 WM THC for the times indicated. B: Cells were cultured in serum-free medium in the presence of
the indicated concentrations of THC for 5 days. In all cases, the medium was renewed every 48 h. The mitochondrial redox state was assessed
by the MTT test as the optical density at 570 nm. Results correspond to 4 di¡erent experiments.
Fig. 2. Micrographs of vehicle- and THC-treated C6.9 glioma cells.
A, B: Phase contrast micrographs. C, D: Binding of £uorescent an-
nexin V. In all cases, cells were treated with or without 1 WM THC
for 5 days as in Fig. 1. Bar: 25 Wm.
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These observations thus indicate that THC-induced glioma
cell death is a process that di¡ers from necrotic death and
displays several features characterizing an apoptotic, pro-
grammed cell death event.
3.2. THC-induced apoptosis may result from sphingomyelin
hydrolysis, and occurs in transformed but not in
non-transformed neural cells
Sphingomyelin hydrolysis is a key process in the control of
many physiological events related to signal transduction and
cellular regulation [23]. In the context of the present study, the
involvement of ceramide (the product of sphingomyelin
breakdown) in the induction of apoptosis is widely docu-
mented [23,24]. Hence we investigated the possible e¡ect of
THC on sphingomyelin hydrolysis. As shown in Fig. 4, the
addition of THC to the cell culture medium produced a sig-
ni¢cant breakdown of cellular sphingomyelin. As previously
shown for other mediators that induce sphingomyelin hydrol-
ysis (e.g. tumor necrosis factor K and interleukin-1) (cf. [23^
25]), the e¡ect of THC was rapid, transient and accounted for
ca. 25% of total cellular sphingomyelin (Fig. 4).
The possibility that THC-induced cell death is not restricted
to C6.9 glioma cells but may be a more general process was
studied by using a number of neural cell types. Thus, the
astrocytoma U373 MG and the neuroblastoma N18 TG2 cell
lines ensued THC-mediated death, although they were not as
sensitive as the C6.9 glioma cell line (Fig. 5). In contrast,
neither astrocytes nor neurons in primary culture were sensi-
tive to the apoptotic action of THC (Fig. 5) even after at least
15 days of challenge to the cannabinoid (data not shown). N-
Acetylsphingosine, a cell-permeable analog of ceramide, dis-
played a similar pattern of cell-death induction as THC, i.e. it
produced the death of the di¡erent transformed neural cell
lines studied but not of primary astrocytes or primary neurons
(Fig. 5). Results therefore suggest that ceramide might be the
mediator of THC-induced apoptosis, although we are aware
that further research is necessary to demonstrate this possibil-
ity.
3.3. THC-induced apoptosis is not mediated by the CB1
cannabinoid receptor
Most of the e¡ects of cannabinoids on the central nervous
system described so far are believed to be mediated by the
CB1 cannabinoid receptor [1]. Hence we next studied whether
the e¡ects of THC described in the present report were also
dependent on this receptor. As shown in Fig. 6, the CB1
receptor was present in C6.9 glioma cells in amounts compa-
rable to those observed in neurons and neuroblastoma N18
TG2 cells. Astrocytes and astrocytoma U373 MG cells also
contained detectable, though lower, amounts of the CB1 re-
ceptor. A particulate fraction from skeletal muscle was used
as a negative control.
The e¡ect of SR141716, a speci¢c high a⁄nity CB1 receptor
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Fig. 4. Stimulation of sphingomyelin hydrolysis by THC in C6.9
glioma cells. Cells were exposed to 1 WM THC for the times indi-
cated and the radioactivity in cellular sphingomyelin (SM) was de-
termined. Results are expressed as percentage of incubations with
no additions and correspond to 6 di¡erent experiments. *Signi¢-
cantly di¡erent (P6 0.01) vs. incubations with no additions.
Fig. 5. THC and N-acetylsphingosine induce the death of trans-
formed but not of non-transformed neural cells. C6.9 glioma cells,
astrocytoma U373 MG cells, neuroblastoma N18 TG2 cells, primary
astrocytes and primary neurons were cultured with 1 WM THC for
5 (C6.9 glioma) or 10 days, with 10 WM N-acetylsphingosine (NAS)
for 3 days, or with 25 WM NAS for 3 days. Results are expressed
as percentage of cell survival with respect to the respective control
incubations as determined by the MTT test and correspond to 4 dif-
ferent cultures for each cell type. *Signi¢cantly di¡erent (P6 0.01)
vs. incubations with no additions.
Fig. 3. THC induces DNA fragmentation in C6.9 glioma cells. Cells
were treated with or without 1 WM THC for 5 days as in Fig. 1. A
representative gel is shown. Similar results were obtained in 2 other
experiments.
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antagonist [26], was tested on THC-induced apoptosis and
THC-induced sphingomyelin breakdown in C6.9 glioma cells.
As shown in Fig. 7A, the THC-induced glioma cell death, as
determined by the MTT test, was not prevented by SR141716.
Likewise, SR141716 was unable to antagonize the THC-in-
duced sphingomyelin hydrolysis (Fig. 7B). These data there-
fore indicate that in spite of the presence of the CB1 receptor
in glioma C6.9 cells the apoptotic e¡ect of THC is not medi-
ated by this receptor. It is worth noting that the THC-induced
metabolic stimulation of C6 glioma cells has been shown to be
prevented by SR141716 [13], indicating that cannabinoids ex-
ert CB1 receptor-dependent and CB1 receptor-independent
actions on those cells. Anyway, the possible existence in glial
cells of a SR141716-insensitive cannabinoid receptor distinct
from CB1 and CB2 has been put forward [27].
3.4. Possible pathophysiological implications
The sphingomyelin cycle has been shown to play a pivotal
role in the regulation of cell function in the central nervous
system [25]. Thus, changes in the activity of the sphingomyelin
cycle, which may in turn be related to the induction of apop-
totic cell death, have been shown to occur during brain devel-
opment as well as in neurodegenerative disorders such as
Alzheimer’s disease, Parkinson’s disease, epilepsy and ische-
mia/stroke [25,28]. Likewise, exposure of neural cells to phys-
ical (e.g. ultraviolet radiation), chemical (e.g. tumor necrosis
factor K), bacterial (e.g. lipopolysaccharide) or viral (e.g. hu-
man immunode¢ciency virus 1) stimuli may trigger sphingo-
myelin breakdown and therefore evoke changes in the cell
survival/cell death decision [23^25]. A ¢nely controlled bal-
ance between di¡erent ceramide-regulated pathways may de-
termine the survival or the death of a particular neural cell
[25]. The possibility that cannabinoids may control the activ-
ity of the sphingomyelin cycle (the present report) and the
mitogen-activated protein kinase cascade [10,12] points there-
fore to a general role of these compounds as modulators of
cell fate. In this respect, it is worth noting that oleoylethanol-
amide, a potential endogenous cannabinoid [1,6], is able to
produce a sustained increase in intracellular ceramide levels
by inhibiting acid ceramidase [29]. Further research is neces-
sary to understand the mechanism of control of the sphingo-
myelin cycle by cannabinoids.
A number of studies are currently focused on potential
therapeutic applications of cannabinoid ligands such as anal-
gesia, antiemesis, antiin£ammation and alleviation of intraoc-
ular pressure in glaucoma [7,8]. Cannabinoids are also being
tested as therapeutic agents in the treatment of neurodegener-
ative diseases such as multiple sclerosis and Parkinson’s dis-
ease [7,8]. The antiproliferative e¡ect of THC described in the
present report might provide the basis for a new therapeutic
application of cannabinoids, especially since primary astro-
cytes and neurons are resistant to the apoptotic action of
THC. In addition, our data suggest that the challenge of
C6.9 cells to cannabinoids may be a useful model to study
the molecular mechanisms involved in apoptosis in cells of
glial origin.
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Fig. 7. Lack of e¡ect of SR141716 on THC-induced death and sphingomyelin hydrolysis in glioma C6.9 cells. A: MTT test. Cells were cultured
for 5 days with vehicle, 1 WM THC, or 1 WM THC plus 2 WM SR141716. B: Sphingomyelin (SM) hydrolysis. Cells were treated with or with-
out 2 WM SR141716 for 30 min prior to the 10-min incubation with 1 WM THC. Results correspond to 3 di¡erent experiments. *Signi¢cantly
di¡erent (P6 0.01) vs. incubations with no additions.
Fig. 6. Presence of the CB1 cannabinoid receptor in transformed
and non-transformed neural cells. Total membrane fractions (10 Wg
total protein per lane) from the di¡erent transformed and non-trans-
formed neural cell lines were subjected to Western blotting with an
antibody raised against the rat CB1 cannabinoid receptor. A repre-
sentative luminogram is shown. Similar results were obtained in
2 other experiments.
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